Biocon shares rise 2% after USFDA approval for Yesintek single-dose prefilled autoinjector
Biocon shares rose after its US subsidiary received supplemental FDA approval for Yesintek single-dose prefilled autoinjectors in two strengths. The approval expands Biocon’s US immunology portfolio, with Yesintek used to treat conditions including plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis.
Biocon's stock price increased by 2% in BSE trading on Tuesday, following the US Food and Drug Administration (FDA) granting supplemental approval for Yesintek's single-dose prefilled autoinjectors. The two new formulations, Yesintek 45 mg/0.5 ml and Yesintek 90 mg/ml, offer patients additional treatment options for autoimmune conditions like plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis.
The company's subsidiary in the United States received the enhanced approval, which complements Biocon's existing immunology product line and underscores its dedication to expanding affordable medicine access globally.
Written by urgent.news from The Economic Times - Top News's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
